Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
Thierry Poynard, Olivier Deckmyn, Marika Rudler, Valentina Peta, Yen Ngo, Mathieu Vautier, Sepideh Akhavan, Vincent Calvez, Clemence Franc, Jean Marie Castille, Fabienne Drane, Mehdi Sakka, Dominique Bonnefont-Rousselot, Jean Marc Lacorte, David Saadoun, Yves Allenbach, Olivier Benveniste, Frederique Gandjbakhch, Julien Mayaux, Olivier Lucidarme, Bruno Fautrel, Vlad Ratziu, Chantal Housset, Dominique Thabut, Patrice Cacoub, Thierry Poynard, Olivier Deckmyn, Marika Rudler, Valentina Peta, Yen Ngo, Mathieu Vautier, Sepideh Akhavan, Vincent Calvez, Clemence Franc, Jean Marie Castille, Fabienne Drane, Mehdi Sakka, Dominique Bonnefont-Rousselot, Jean Marc Lacorte, David Saadoun, Yves Allenbach, Olivier Benveniste, Frederique Gandjbakhch, Julien Mayaux, Olivier Lucidarme, Bruno Fautrel, Vlad Ratziu, Chantal Housset, Dominique Thabut, Patrice Cacoub
Abstract
Background: Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19.
Methods: We compared the daily mean serum apolipoprotein-A1 during the first 34 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (212,297 serum) and in France (20,652 serum) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (266,976 and 28,452 serum, respectively). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population.
Results: The mean serum apolipoprotein-A1 levels in the survey populations began decreasing in January 2020, compared to the same period in 2019. This decrease was highly correlated with the daily increase in confirmed Covid-19 cases in the following 34 weeks, both in France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio of apolipoprotein-A1 for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0; P = 0.04).
Conclusion: Apolipoprotein-A1 could be a sentinel of the pandemic in existing routine surveillance of the general population. NCT01927133, CER-2020-14.
Conflict of interest statement
TP has several USPTO patents related to the performance of Apoa1 in patients with liver disease, including #10,198,552 Method of diagnosis of fibrotic diseases, #7,860,656 Diagnosis method of hepatic steatosis using biochemical markers, 7,856,319, Diagnosis method of alcoholic steato-hepatitis using biochemical markers, #7,225,080 Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers, and # 6,631,330 Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers, and applications pending: #20200011879 Method of diagnosis of drug induced liver injury, 20190265241 Method of diagnosis of non-alcoholic fatty liver diseases, #3 20140329260 Method of diagnosis of fibrotic diseases, and #20090111132 Diagnosis method of hepatic steatosis using biochemical markers. The data underlying the findings described in the manuscript are fully detailed including the confounding factors, without restriction, in the numerous supplementary files. The commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Wynants L, Van Calster B, Collins G, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of Covid-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328 10.1136/bmj.m1328
- Kipp HA. Variation in the cholesterol content of the serum in pneumonia. J Biol Chem. 1920; 44:215–237.
- Liu SH, Liang HY, Li HY, Ding XF, Sun TW, Wang J, et al. Effect of low high-density lipoprotein levels on mortality of septic patients: A systematic review and meta-analysis of cohort studies. World J Emerg Med. 2020;11(2):109–116. 10.5847/wjem.j.1920-8642.2020.02.008
- Delanghe JR, Langlois MR, Boelaert JR, Van Acker J, Van Wanzeele F, Van der Groen G, et al. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS. 1998; 12(9):1027–32.
- Yang H, Wang H, Wang Y, Addorisio M, Li J, Postiglione MJ, et al. The haptoglobin beta subunit sequesters HMGB1 toxicity in sterile and infectious inflammation. J Intern Med. 2017;282(1):76–93. 10.1111/joim.12619
- Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020;14(3):297–304. 10.1016/j.jacl.2020.04.008
- Cao X, Yin R, Albrecht H, Fan D, Tan W. Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2? Am J Physiol Endocrinol Metab. 2020;319(1):E197–E202. 10.1152/ajpendo.00255.2020
- Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–54. 10.1126/science.abc1669
- Ding S, Liang TJ. Is SARS-CoV-2 Also an enteric pathogen with potential fecal-oral Transmission? A COVID-19 virological and clinical review. Gastroenterology. 2020;159(1):53–61. 10.1053/j.gastro.2020.04.052
- Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357(9262):1069–75. 10.1016/S0140-6736(00)04258-6
- Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–430. 10.1016/S2468-1253(20)30057-1
- Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, et al. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PloS One. 2017; 12(12):e0189436 10.1371/journal.pone.0189436
- Rudler M, Mouri S, Charlotte F, Cluzel P, Ngo Y, Munteanu M, et al. Validation of AshTest as a non-invasive alternative to transjugular liver biopsy in patients with suspected severe acute alcoholic hepatitis. PLoS One. 2015;10(8):e0134302 10.1371/journal.pone.0134302
- Perazzo H, Pais R, Munteanu M, Ngo Y, Monneret D, Imbert-Bismut F, et al. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c’est fini? ". Clin Res Hepatol Gastroenterol. 2014;38(4):432–9. 10.1016/j.clinre.2014.04.006
- Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2019;69(2):760–773. 10.1002/hep.29802
- Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010;10:40 10.1186/1471-230X-10-40
- Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol. 2011;11:39 10.1186/1471-230X-11-39
- Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369(6500):208–211. 10.1126/science.abc3517
- Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;92(7):903–908. 10.1002/jmv.25786
- Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8 10.1038/s41368-020-0074-x
- Danielsen EM, Hansen GH, Rasmussen K, Niels-Christiansen LL, Frenzel F. Apolipoprotein A-1 deposition in, and release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux (TICE)? Biochim Biophys Acta. 2012;1818(3):530–6. 10.1016/j.bbamem.2011.11.011
- Gates B. Responding to Covid-19. A Once-in-a-Century Pandemic? New Engl J Med. 2020; 382(18):1677–1679. 10.1056/NEJMp2003762
Source: PubMed